Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 16Thoracic 4Gynecologic 4Head & Neck 3Genitourinary 3Gastrointestinal 3Dermatologic 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Carcinoma, Transitional Cell 29Urinary Bladder Neoplasms 26Carcinoma, Renal Cell 22Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Ureteral Neoplasms 5Prostatic Neoplasms 5Ovarian Neoplasms 5Melanoma 5Carcinoma, Merkel Cell 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Penile Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Turcot syndrome 1Testicular Neoplasms 1

Interventions

pembrolizumab 27Docetaxel 20Cyclophosphamide 18Surveys and Questionnaires 15Therapeutics 14Radiotherapy 13Paclitaxel 12Psychiatric Rehabilitation 11Early Intervention, Educational 11Carboplatin 11Standard of Care 10olaparib 9Zoledronic Acid 9Specimen Handling 9Radiosurgery 9Magnetic Resonance Spectroscopy 9Interviews as Topic 9Gemcitabine 9Trastuzumab 8Methods 8Fulvestrant 8palbociclib 7fludarabine 7durvalumab 7Taxes 7Nivolumab 7Fluorodeoxyglucose F18 7Flow Cytometry 7Educational Status 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × avelumab × Genitourinary × Clear all
NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT01772004 2021-12-20

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

EMD Serono

Phase 1 Completed
1,756 enrolled 59 charts
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡